U.S. stock market update: Scribe Therapeutics down 12.03%, stock price pressured by clinical delay in gene editing

U.S. Stock Market Midday Update

Scribe Therapeutics fell 12.03%. Based on recent key news:

1. On July 27, Scribe Therapeutics announced that clinical trial data for its gene editing drug is expected to be released in the first half of 2027. The company plans to start human trials in 2027 or 2028, which has raised market uncertainty about its future development, leading to a decline in stock price.

2. The overall market performance has been weak recently, with the Renaissance IPO Index dropping 2.5% last week, while the S&P 500 Index only fell 0.6%. The low market sentiment may have negatively impacted Scribe Therapeutics' stock price.

3. On July 27, the market held a wait-and-see attitude towards Scribe Therapeutics' long-term development strategy, especially regarding the progress of its gene editing drug's clinical trials. Investors' concerns about its future profitability intensified, putting pressure on the stock price. The gene editing industry faces technological and regulatory challenges.

Top Stocks by Industry Trading Volume

Forte Biosciences rose 39.51%, with a trading volume of $1.019 billion, achieving a 139.58% increase over the past six months, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

AbbVie rose 0.02%. Based on recent key news:

1. On July 27, the U.S. stock market faced a busy week of earnings releases and policy signals, which may affect market expectations and valuations. Several companies, including ABBV, will release earnings this week, and the Federal Reserve's interest rate decisions and economic data will also impact market sentiment, increasing short-term volatility;

2. On July 25, AbbVie attracted attention with its 2.7% attractive dividend yield and robust pharmaceutical business. The company's focus on dividend policy has drawn investor interest, supporting stock price stability;

3. On July 26, analysts held an optimistic view of AbbVie's future prospects. Despite market volatility, analysts believe the company has good long-term development potential, enhancing investor confidence. Capital is flowing into large tech stocks, increasing volatility.

Amgen rose 0.37%. Based on recent key news:

1. On July 25, European drug regulators recommended withdrawing the approval of Tavneos, citing unreliable research data. Tavneos is used to treat severe ANCA-associated vasculitis, and this decision may affect Amgen's market performance.

2. In June, the European drug regulators' recommendation raised market concerns about the safety of Amgen's drugs, leading to fluctuations in investor sentiment.

3. In March, health regulators found that Tavneos was associated with severe liver injury cases, including eight deaths, which intensified the market's negative view of the drug. The pharmaceutical industry faces regulatory pressure, and market volatility has increased Stocks Ranked Among the Top by Market Capitalization in the Industry

Gilead Sciences rose by 1.86%. Based on recent key news:

1. On July 23, BMO Capital assigned a buy rating to Gilead Sciences, driving the stock price up. Analysts believe the company performs excellently in the healthcare sector, setting a target price of $120.

2. On July 20, Goldman Sachs maintained a hold rating on Gilead Sciences, with a muted market response. Analysts are cautious about the company's long-term growth.

3. On July 25, MarketBeat did not include Gilead Sciences in its recommended buy list, indicating a cautious market attitude towards its short-term performance. The overall performance of the healthcare industry remains stable, with significant capital inflows